Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Product availability: Stock levels and vial size availability are subject to change based on manufacturer supply
Was the finished product tested
Let us know if you need help
User reports are mixed on this point
What the evidence supports: BPC-157 consistently improves tendon healing outcomes in animal models across multiple tissue types and injury models TB-500 accelerates wound healing and tissue repair in preclinical studies with measurable improvements in re-epithelialization, collagen deposition, and angiogenesis GHK-Cu enhances collagen synthesis and modulates thousands of genes involved in tissue repair GHRP-2 shifts macrophage polarization favorably in a rotator cuff tear model Relaxin-2 eliminates capsular fibrosis in a frozen shoulder mouse model No significant toxicity has been identified in preclinical BPC-157 studies What remains uncertain: Whether animal study results translate to equivalent human outcomes for shoulder conditions specifically Optimal dosing for human shoulder injuries (all protocols are extrapolated from animal data and clinical observation) Long-term safety with repeated use Whether peptides meaningfully reduce rotator cuff retear rates after surgical repair in humans How peptide therapy compares to established treatments like PRP in controlled human studies Potential interactions with medications commonly used by shoulder pain patients What we need: Randomized controlled trials of BPC-157 and TB-500 for specific shoulder conditions in humans Head-to-head comparisons of peptide therapy versus established treatments Long-term safety data from monitored human use Standardized dosing protocols based on human pharmacokinetic data Studies combining peptides with rehabilitation to assess synergistic effects The preclinical evidence is compelling
When a pain blocker wears off, the pain returns
